Articles by Sean D. Sullivan, PhD
Validation of the FINE-CKD Model for Future Health Technology Assessments for Finerenone in Patients With Chronic Kidney Disease And Type 2 Diabetes
ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Aleksandra Drzewiecka, MSc,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Monika Palarczyk, MSc,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
ByKai Yeung, PharmD, PhD,Anirban Basu, PhD,Zachary A. Marcum, PharmD, PhD,John B. Watkins, PharmD, MPH, BCPS,Sean D. Sullivan, PhD A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects
ByLouis P. Garrison Jr, PhD,Josh J. Carlson, PhD,Preeti S. Bajaj, PhD,Adrian Towse, MA, MPhil,Peter J. Neumann, ScD,Sean D. Sullivan, PhD,Kimberly Westrich, MA,Robert W. Dubois, MD, PhD Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.
Increasing Pharmaceutical Copayments: Impact on Asthma Medication Utilization and Outcomes
ByJonathan D. Campbell, PhD, MS,Felicia Allen-Ramey, PhD,Shiva G. Sajjan, PhD,Eric M. Maiese, PhD,Sean D. Sullivan, PhD Even small changes in average copayment for long-term controller asthma medications can result in significant reductions in medication use and increases in healthcare services.
Colony-Stimulating Factor Prescribing Patterns in Patients Receiving Chemotherapy for Cancer
ByScott D. Ramsey, MD, PhD,Jeannine S. McCune, PharmD,David K. Blough, PhD,Cara L. McDermott, BA,Lauren Clarke, MS,Jennifer L. Malin, MD, PhD,Sean D. Sullivan, PhD We linked health insurance records to cancer registry data to analyze colony-stimulating factor use, finding wide divergence from that recommended by practice guidelines.
Quality of Clinical and Economic Evidence in Dossier Formulary Submissions
ByFernando Colmenero, MD,Sean D. Sullivan, PhD,Jennifer A. Palmer, MS,Carmen A. Brauer, MD,Kathleen Bungay, PharmD,John Watkins, RPh, MPH,Peter J. Neumann, ScD Toward Evidence-based Assessment for Coverage and Reimbursement of Laboratory-based Diagnostic and Genetic Tests
ByScott D. Ramsey, MD, PhD,David L. Veenstra, PharmD, PhD,Louis P. Garrison Jr, PhD,Rick Carlson, JD,Paul Billings, MD, PhD,Josh Carlson, MS,Sean D. Sullivan, PhD Incorporating Clinical Outcomes and Economic Consequences into Drug Formulary Decisions: A Practical Approach
ByDell B. Mather, PharmD,Sean D. Sullivan, PhD,Darren Augenstein, PharmD, MBA,D. S. Pete Fullerton, PhD, RPh,Debbie Atherly, RPh, MPH